FUNDAMENTAL AND CLINICAL STUDIES OF IMIPENEM/CILASTATIN SODIUM IN THE SURGICAL FIELD

• Published in: CHEMOTHERAPY Vol. 33; no. Supplement4; pp. 969 - 981
• Main Author: YURA, JIRO
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1985
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.33.Supplement4_969

Fundamental and clinical studies of imipenem/cilastatin sodium (MK-0787/MK-0791) in the surgical field were performed and the following results were obtained: 1) Antibacterial activity Peak MICs of MK-0787 against S.aureus, E.coli, Klebsiella sp. and P.aeruginosa were 0.05, 0.2, 0.2 and 0.8 μg/ml, respectively. MICs of MK-0787 against S.aureus and P.aeruginosa were lower than those of either latamoxef and gentamicin. 2) Biliary excretion Biliary excretion of MK-0787 was lower than that of cefoxitin in 3 patients with T-tubes in their common bile ducts. 3) Clinical results MK-0787/MK-0791 was administered to 38 patients with surgical infections, and the clinical results were excellent in 6, good in 22, fair in 6, poor in 2 and unknown in 2. No adverse reaction was demonstrated. Abnormal laboratory findings were noticed in 7 patients during the administration of the drug.